Immunohistochemical analysis of expression of bcl-2 protein in papillary carcinomas and papillary microcarcinomas of the thyroid gland

Απλή σελίδα τεκμηρίου
dc.contributor.authorMitselou, A.en
dc.contributor.authorPeschos, D.en
dc.contributor.authorDallas, P.en
dc.contributor.authorCharalabopoulos, K.en
dc.contributor.authorAgnantis, N. J.en
dc.contributor.authorVougiouklakis, T.en
dc.date.accessioned2015-11-24T19:12:02Z
dc.date.available2015-11-24T19:12:02Z
dc.identifier.issn1812-9269-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21003
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectCarcinoma, Papillary/*genetics/pathologyen
dc.subjectDisease Progressionen
dc.subjectFemaleen
dc.subject*Gene Expression Profilingen
dc.subjectHumansen
dc.subjectImmunohistochemistryen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Stagingen
dc.subjectPrognosisen
dc.subjectProto-Oncogene Proteins c-bcl-2/*biosynthesis/*geneticsen
dc.subjectThyroid Neoplasms/*genetics/pathologyen
dc.titleImmunohistochemical analysis of expression of bcl-2 protein in papillary carcinomas and papillary microcarcinomas of the thyroid glanden
heal.abstractAIM: To compare the expression of anti-apoptotic protein bcl-2 and tissue proliferation Ki-67 antigen in tissues of human papillary thyroid carcinoma (PTC) and papillary thyroid microcarcinoma (PTMC). METHODS: Bcl-2 protein expression in PTC and PTMC has been evaluated by immunohistochemical analysis. RESULTS: Bcl-2 protein was observed in normal thyroid gland in all the cases; in 25% of the cases of papillary carcinomas the immunoreaction was strong and in 75% of the cases--moderate. In 25% of the cases of papillary microcarcinomas the bcl-2 expression was totally negative and 35% was moderate. Bcl-2 expression was lower in non-sclerosing non-encapsulated (NSNE) (25%) cases of PMCs than in non-sclerosing encapsulated (NSE) (57.15%) cases of PTMCs (p < 0.05). MIB-1/Ki-67 expression was notably reduced or not expressed in normal and benign thyroid tissue. MIB-1 immunoreactivity was present in papillary carcinoma, and on a lower level--in PTMCs. The MIB-1 labelling index of NSE and sclerosing non-encapsulated (SNE) cases was lower than that in NSNE (p < 0.005). CONCLUSION: The present study indicated that NSNE cases of PTMCs may be an early stage in tumor progression, and the bcl-2 and MIB-1 immunohistochemistry may be a valuable tool in predicting the malignant behavior in PMTCs, and contributes to the understanding the growth characteristics of papillary carcinomas of the thyroid gland.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15627060-
heal.journalNameExp Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2004-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ